期刊文献+

氯诺昔康对心内直视手术后患者自控镇痛效应的影响

Effects of lornoxicam on patient controlled analgesia in patients after open heart surgery
下载PDF
导出
摘要 目的:观察氯诺昔康对心内直视手术后患者自控镇痛效应的影响。方法:将30例心内直视手术患者随机分为氯诺昔康组和吗啡组,每组各15例。镇痛药为吗啡1mg/mL,参数设置为:负荷剂量1mg,持续输注剂量0.5mg/h,单次给药剂量1mg,锁定时间10min,每4h最大限量20mg。应用PCA泵的同时,氯诺昔康组静脉注射首剂氯诺昔康8mg,首剂药物后12、24和36h,静脉注射氯诺昔康8mg;吗啡组在四时间点均注射生理盐水。镇痛开始后12、24、36和48h记录疼痛VAS评分,PCA需求按压次数和有效按压次数,药物用量,镇静程度评分;术后各种并发症及不良反应发生率;记录镇痛满意度NRS评分。结果:两组患者各时间点安静痛和咳嗽痛评分差异无统计学意义(P>0.05)。镇静程度评分、PCA需求按压次数、有效按压次数及药物用量氯诺昔康组显著低于吗啡组(P<0.05)。两组患者氯诺昔康组恶心发生率显著低于吗啡组(P<0.05),其他术后各种并发症及不良反应发生率差异无统计学意义(P>0.05)。两组患者对镇痛满意度评分、在ICU停留时间及手术后住院时间差异无统计学意义(P>0.05)。结论:氯诺昔康可安全有效地应用于心内直视手术后患者术后镇痛,并减少吗啡用量。 AIM: To observe the effects of lomoxicam on patient controlled analgesia in patients after open heart surgery. METHODS: Thirty patients were randomly allocated to lornoxicam group (n = 15) and morphine group ( n = 15). Both groups received PCA (patient controlled analgesia ) with morphine (1 mg/mL). The PCA parameters were morphine loading dose of 1 mg, continuous infusion dose of 0.5 mg/h, single dose of 1 mg, lockout time of 10 min, and 4 hours limit of 20 mg. Lomoxicam group received intravenous lomoxicam of 8 mg while the PCA pump beginning, 12, 24 and 48 h after the first dose. Morphine group received intravenous normal saline at the same four points. The following indexes were recorded at 12, 24, 36 and 48 h after the PCA pumps were used: VAS scores of pain, effective pressing numbers, drug dosage, sedation degree, side effects, and patient satisfaction. RESULTS: There were no significant difference in VAS scores of pain at 12, 24, 36 and 48 hours after the PCA pumps were used( P 〉 0.05). The VAS scores of pain, effective pressing numbers and drug dose in lornoxicam group were obviously lower than those in morphine group ( P 〈 0.05). The incidence rate of nausea in lomoxicam group was obviously lower than that in morphine group ( P 〈 0.05 ), and there were no significant difference of the other side effects (P 〉 0.05). There were no significant difference in patient satisfaction degree, residence time in ICU and length of stay after operation ( P 〉 0.05 ). CONCLUSION: Lomoxicam can relief pain in patients after open heart surgery safely and efficiently, and reduce the morphine consumption.
出处 《中国临床药理学与治疗学》 CAS CSCD 2008年第8期934-937,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 氯诺昔康 心脏外科 手术 镇痛 患者控制 lomoxicam heart surgery operation analgesia patient-controlled
  • 相关文献

参考文献10

  • 1赵晶,叶铁虎,罗爱伦.镇痛药物及其应用[J].中国临床康复,2002,6(16):2350-2352. 被引量:49
  • 2Mueller XM, Tinguely F, Tevaearai HT, et al. Pain location, distribution, and intensity after cardiac surgery[ J]. Chest, 2000, 118(2) :391 - 396.
  • 3Memis D, Bryhan K, Turanl A, et al. Effects of lornoxicam on the physiology of severe sepsis[J]. Critical Care, 2004,8(6) :474 - 482.
  • 4Berg J, christoph T, Widerna M, et al. Isoenzyme-specific cyclooxygenase inhibitirs: A whole cen assay ayatem using the human erythrolukemic cenrl line HEL and the human monocytic ceril line monomai6[J]. J Pharmacol Toxicaol Meth, 1997,37( 1 ) : 179 - 186.
  • 5Sandle AN, Kat ZJ. Postoperative analgesia and patient satisfaction[J]. Can J Anaesth, 1994,41 ( 1 ) : 1 - 4.
  • 6Rosenow DE, Albrechtsen M, Stolke D . A Comparison of patient-controlled analgesia with lomoxicam versus morphine in patients undergoing lumbar disk surgery[ J ]. Anesth Analg, 1998,86(5) : 1045 - 1050.
  • 7Karamanlioglu B, Turan A, Memis D , et al. Infiltration with ropivacaine plus lomoxicam reduces postoperative pain and opioid consumptiou[J]. CAN J Anesth, 2005,52 (10) : 1047 - 1053.
  • 8龚志毅,叶铁虎,于广祥,秦晓涛,郭向阳,罗爱伦.氯诺昔康用于妇科开腹手术后病人自控镇痛的临床研究[J].中华麻醉学杂志,2001,21(9):531-533. 被引量:121
  • 9施文,王永铭,程能能,陈斌艳,李端.非甾体类抗炎药的不良反应研究进展[J].中国临床药理学杂志,2003,19(1):57-62. 被引量:60
  • 10崔旭蕾,郭向阳,任洪智.非甾体抗炎药及其心血管风险[J].临床麻醉学杂志,2007,23(3):256-257. 被引量:14

二级参考文献55

  • 1[1]Lichtenstein D, Syngal S, Wlfe MM. Non-steroidal antiinflammatory drugs and the gastrointestinal tract. Arthritis Rherm,1995;38:1:5~18.
  • 2[2]Bjarnason I, Macpherson A, Somasundaram S, et al. Lower bowel toxicity of non-steroidal anti-inflammatory drugs. Lewis A: Non-steroidal Anti-Inflammatory Drugs, Mechanisms and Clinical Uses. New York: NY, Marcel Dekker, 1994;145~157.
  • 3[3]Marie R, Griffin, MD. Epidemiology of non-steroidal antiinflammatory drug-associated gastrointestinal injury. Am J Med.1998;104: 23~28.
  • 4[4]Fujiwara Y, Schmassman A, Arakawa T, et al. Indomethacin interferes with epidermal growth factor binding and proliferative response of KATO Ⅲ cells. Digestion, 1995;56:364~369.
  • 5[5]Henry D, Robertson J. Non-steroidal anti-inflammatory drugs and peptic ulcer hospitalization rates in New South Wales.Gastroenterology. 1993; 104:1083~ 1091.
  • 6[6]Fries JF, Williams CA, Michel BA et al. Nonsteroidal antiinflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med, 1991 ;91:213 ~222.
  • 7[7]Gutthamm SP, García LA, Raiford DS. Individual nonsteroidal anti-inflammatory drugs and the risk of hospitalization for upper gastrointestinal bleeding and perforation in saskatche wan: a nested case-control study. Pharmacoepidemiol Drug Safety. 1994;3:S63.
  • 8[8]Loeb DS, Talley NJ, Ahlquist DA, et al. Long-term non-steroidal anti-inflammatorydrug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology, 1992;102 :1899~1905.
  • 9[9]Langman MJS, Weil J, Wainwright P, et al. Risk of bleeding peptic ulcer associated with individual non-steroidal antiinflammatory drugs. Lancet, 1994 ;34 3 :107 5-107 8
  • 10[10]Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. am J Med, 1999;106:13~23.

共引文献233

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部